European Commission approves Sanofi’s MenQuadfi vaccine for infants from 6 weeks, expanding early protection against meningococcal disease

Sanofi’s MenQuadfi now approved for infants as young as 6 weeks in the EU, offering earlier protection against invasive meningococcal disease and its serious complications, including hearing loss. The European Commission has cleared Sanofi’s MenQuadfi vaccine for use in infants…















